हिंदी में पढ़ें

Sun Pharma Advanced Research company (SPARC)

Sun Pharma Advanced Research Q4 net loss widens to Rs 81.99 crore

Sun Pharma Advanced Research Q4 net loss widens to Rs 81.99 crore

Mon, May 22, 2023

The company had posted a net loss of Rs 71.05 crore in the same period previous fiscal, Sun Pharma Advanced Research Company said in a regulatory filing.

SPARC signs licensing pact with Visiox Pharma for ophthalmic products

SPARC signs licensing pact with Visiox Pharma for ophthalmic products

Wed, Dec 08, 2021

The company has entered into an agreement with Visiox Pharma LLC (Visiox) to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialisation of PDP-716 and SDN-037, SPARC said in a statement.

SPARC's net loss widens to Rs 36 crore

SPARC's net loss widens to Rs 36 crore

Fri, Jul 29, 2016

SPARC reported widening of standalone net loss to Rs 36.41 crore for the first quarter ended June 30. The company had posted a net loss of Rs 1.65 crore for the corresponding period of the previous fiscal.

TRENDING NOW

Sun, Dr Reddy's, Glenmark strengthen their US play

Sun, Dr Reddy's, Glenmark strengthen their US play

Mon, Jul 18, 2016

Domestic pharma players are in stiff competition in US market. Sun Pharma with its taking over of SPARC's ELEPSIA XR, while Dr. Reddy launching Omeprazole and Sodium bicarbonate capsules and that of Glenmark waiting for 62 ANDA's approval, plans to strenghthen their position in the US.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x